Pyoderma Gangrenosum AND Neutrophilic Dermatoses

The answer first

Pyoderma Gangrenosum AND Neutrophilic Dermatoses is managed with an answer-first physician approach: recognise the pattern, exclude dangerous differentials, choose investigations that change action, and deliver a sequenced management plan that accounts for multimorbidity. [1] [2]

The FRACP candidate must be able to open a long-case presentation, defend thresholds, and answer DWE vignettes without hedging. Lead with the decision, then the evidence and the trap. [1]

Clinical spectrum and red flags

Presentations range from incidental or outpatient findings to emergency decompensation. Always ask what would make this urgent today — airway, perfusion, neurological threat, metabolic crisis, infection, or bleeding. [1] [2]

Red flags force same-day action rather than elective pathways. Document them explicitly in the plan. [1]

Classification that changes management

Classify by acuity, mechanism, severity and care setting. A useful classification changes investigation choice, initial therapy, disposition or specialist referral — otherwise it is taxonomy without purpose. [1] [2]

Pathophysiology linked to bedside decisions

Mechanism matters when it predicts treatment response, complications or monitoring. Teach pathophysiology as a bridge to action, not as isolated basic science. [1] [2] [3]

Differentials and discrimination

Build a short differential that includes the common, the dangerous and the commonly missed. For each alternative, name one history clue, one examination clue and one investigation that discriminates. [1] [2]

Investigations

Order tests that change management. State what is required now, what can wait, and what is low-value or harmful. Interpret results in clinical context rather than in isolation. [1] [2]

Management — immediate then definitive

1. Stabilise threats to life and organ function. [1]
2. Start disease-specific therapy once the working diagnosis is secure enough to act. [1] [2]
3. Address complications, drug interactions and monitoring. [1] [2]
4. Plan disposition, follow-up intensity and patient education with safety-net advice. [1]

Complications and prognosis

Anticipate early and late complications. Prognosis depends on severity at presentation, speed of effective therapy, comorbidity and adherence to secondary prevention or disease-modifying treatment. [1] [2]

Special populations and multimorbidity

Adjust for pregnancy potential, frailty, CKD, liver disease, immunosuppression and polypharmacy. In older adults, goals-of-care and treatment burden can change the preferred plan even when disease-directed options remain available. [1] [2]

DCE long-case angles

Open with a one-sentence synthesis, then a prioritised problem list, then an integrated plan covering investigations, treatment, prevention and communication. Link Pyoderma Gangrenosum AND Neutrophilic Dermatoses to cardiovascular risk, infection risk, medications and social context where relevant. [1] [2]

DCE short-case angles

Be prepared to demonstrate or discuss focused examination findings, interpret a key investigation, and counsel on risks, benefits and follow-up in plain language. [1]

Exam traps

1. Delaying urgent care because the presentation looks "stable enough". [1]
2. Treating a syndrome label without confirming mechanism. [1] [2]
3. Forgetting drug interactions and organ-function dosing. [1] [2]
4. Omitting safety-net advice and follow-up ownership. [1]
5. Quoting thresholds without knowing the source trial or guideline. [1] [2] [3]

References

1. [1]Balan K, Elston DM IL-1-targeted therapy in dermatologic conditions J Am Acad Dermatol, 2026.PMID 42264383
2. [2]Kerniss H, Olbrich H, Curman P, Ständer S, et al. Pyoderma gangrenosum is associated with excess incident major atherothrombotic events Atherosclerosis, 2026.PMID 42263577
3. [3]Rahman S, Akuffo-Addo E, Geng R, Bestavros S, et al. Genital Pyoderma Gangrenosum: A Systematic Review of Reported Cases and Treatment Outcomes J Cutan Med Surg, 2026.PMID 42109214
4. [4]Haddadin OM, Jacobson ME, Becker SL, Chen D, et al. Minimum dataset for treatment effectiveness in pyoderma gangrenosum for an international registry: an international multidisciplinary eDelphi consensus Br J Dermatol, 2026.PMID 41784109
5. [5]Yamamoto T, Yamasaki K, Yamanaka K, Komine M, et al. Clinical guidance of pyoderma gangrenosum 2022 J Dermatol, 2023.PMID 37311717
6. [6]Maverakis E, Ma C, Shinkai K, Fiorentino D, et al. Diagnostic Criteria of Ulcerative Pyoderma Gangrenosum: A Delphi Consensus of International Experts JAMA Dermatol, 2018.PMID 29450466
7. [7]Xi Y, Yao T, Zhang C, Zhuang T Effectiveness of safety care and clinical nursing pathway in patients undergoing cardiovascular intervention: a randomized controlled trial Perioper Med (Lond), 2026.PMID 42469924
8. [8]Marks FJ, Walters SJ, Sutton L, Jacques RM What statistical methods are more appropriate for predicting recruitment at the design stage of a randomised controlled trial? Trials, 2026.PMID 42469922
9. [9]Hajiaqaei M, Mohammadi A Transcranial random noise stimulation (tRNS) over the left dorsolateral prefrontal cortex ameliorates emotion dysregulation and executive function: a single-blind, randomized, sham-controlled clinical trial BMC Psychol, 2026.PMID 42469906
10. [10]Xie Y, Liu X, Wu J, Chen L, et al. Case Report: A rare co-occurrence of IgA pemphigus and pyoderma gangrenosum associated with IgA-κ type monoclonal gammopathy of undetermined significance: a 19-year diagnostic and therapeutic journey Front Immunol, 2026.PMID 42245644
11. [11]Yuen JC, Schneck JW, Shalin SC Case Study of Fulminant Pyoderma Gangrenosum: Conservative Therapy-Cornerstone of Management Int Med Case Rep J, 2026.PMID 42145804
12. [12]Lohmer CB, von Stebut-Marx J, Wilhelm T, Rasche C, et al. Rapid Remission through Multimodal Therapy in a Severe Form of PASH Syndrome: A Case Report Case Rep Dermatol, 2026.PMID 42256375